QianJin Pharmaceutical released its semi-annual performance, with a net profit attributable to the parent company of 128 million yuan, a year-on-year increase of 8.5%

According to the Zhitong Finance APP, QianJin Pharmaceutical disclosed its semi-annual report for 2025. During the reporting period, the company achieved revenue of 1.818 billion yuan, a year-on-year decrease of 5.52%; net profit attributable to the parent company was 128 million yuan, a year-on-year increase of 8.5%; net profit excluding non-recurring gains and losses was 118 million yuan, a year-on-year increase of 6.58%; basic earnings per share were 0.3012 yuan